



Newfoundland and Labrador Pharmacy Board

At their meeting on September 9, 2016, the Newfoundland and Labrador Pharmacy Board approved the following changes to the Provincial Drug Schedules:

1. esomeprazole and its salts

To reflect the NDSAC recommendation of March 16, 2016, and finalized on April 15, 2016.

Amended in Schedule I: “esomeprazole or its salts, except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole”

Added to Schedule II: “esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole”

2. fluticasone propionate

To reflect the NDSAC recommendation of March 16, 2016, and finalized on April 15, 2016.

Amended in Schedule I: “fluticasone propionate, except when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.”

Added to Schedule II: “fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 120 metered sprays”

Added to Schedule III: “fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 120 metered sprays”

3. ibuprofen and its salts

To reflect the NDSAC recommendation of March 16, 2016, and finalized on April 15, 2016.

Amended in Schedule I: “Ibuprofen or its salts, except when sold in an immediate release form for oral administration in a concentration of 400 mg or less per dosage unit or when sold in a modified release oral dosage form that provides 600 mg or less per dosage unit.”

Added to Schedule III: “ibuprofen or its salts, when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit”